Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Aytu Biopharma (AYTU) over the last 17 years, with Jun 2025 value amounting to $124.2 million.

  • Aytu Biopharma's Liabilities and Shareholders Equity rose 7.91% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $489.6 million, marking a year-over-year decrease of 0.90%. This contributed to the annual value of $124.2 million for FY2025, which is 5.15% up from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Liabilities and Shareholders Equity is $124.2 million, which was up 5.15% from $118.1 million recorded in FY2024.
  • Aytu Biopharma's Liabilities and Shareholders Equity's 5-year high stood at $265.7 million during FY2021, with a 5-year trough of $118.1 million in FY2024.
  • For the 3-year period, Aytu Biopharma's Liabilities and Shareholders Equity averaged around $126.2 million, with its median value being $124.2 million (2025).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first spiked by 73.31% in 2021, then tumbled by 48.20% in 2022.
  • Yearly analysis of 5 years shows Aytu Biopharma's Liabilities and Shareholders Equity stood at $265.7 million in 2021, then slumped by 48.20% to $137.6 million in 2022, then decreased by 0.84% to $136.5 million in 2023, then declined by 13.46% to $118.1 million in 2024, then grew by 5.15% to $124.2 million in 2025.